| Ytd | -6.53% | |
| 1y | 108.40% |
| Open | 7.02 | Prev Close | 7.04 | Low | 6.98 | High | 7.49 | Mkt Cap | 400.89M |
| Vol | 275.99K | Avg Vol | 192.81K | EPS | -0.71 | P/E | N/A | Forward P/E | -7.26 |
| Beta | 1.46 | Short Ratio | 3.88 | Inst. Own | 31.61% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 6.09 | 200-d Avg | 7.17 | 1yr Est | 7.00 |
DMAC News
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause
DiaMedica believes, based on the FDA's feedback, that the previously completed rat reproductive
ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified I
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which met the an
DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarte
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on dev
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company developing nov
Cantor Fitzgerald analyst Josh Schimmer initiates coverage on DiaMedica Therapeutics (NASDAQ:DMAC
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.17) per share which met the an
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC)
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.18) per share which beat the a
Craig-Hallum analyst Chase Knickerbocker maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Bu
Lake Street analyst Thomas Flaten maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and r
HC Wainwright & Co. analyst Matthew Caufield maintains DiaMedica Therapeutics (NASDAQ:DMAC) w
Conference Call Today July 17, 2025 at 4:30 PM Eastern Time / 3:30 PM Central TimeDM199 Demonstrated
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC)
Company to Host Preeclampsia Key Opinion Leader Event May 28, 2025 at 8 AM Eastern / 7 AM CentralDia
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.18) per share which met the an
HC Wainwright & Co. analyst Matthew Caufield maintains DiaMedica Therapeutics (NASDAQ:DMAC) w
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.60) per share which missed the
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC)
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.15) per share which met the an
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC)
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on DiaMedica Therapeutics (NA
Oppenheimer analyst Francois Brisebois reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Out
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.13) per share which beat the a
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM CentralW
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on dev
Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 20
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.14) per share which beat the a
Craig-Hallum analyst Alexander Nowak assumes DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy rati
Craig-Hallum analyst Alexander Nowak maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy an